MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
About this episode
This episode discusses the evolving treatment options and management strategies for Neurofibromatosis type 1 and the role of nursing in managing plexiform neurofibromas.
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary te...
More episodes of CEConversations
- A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
- Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
- Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
- Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
- Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
- The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
Explore listener stats, chart rankings, contacts and more on the CEConversations podcast page.